Spigelman Melvin K

Spigelman Melvin K is listed in filings as Director at AN2 Therapeutics, Inc.. This profile follows SEC Form 4 activity through Mar 23, 2026, including 9 public disclosures. Recent filings connect the profile to AN2 Therapeutics, Inc. (ANTX). The current snapshot covers public activity from Jun 21, 2024 to Mar 23, 2026. Reported amounts are shown as $179.1K to $140.3K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.